AMCR vs TSCO

AMCR's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($29.87) and intrinsic value ($10.92), supported by a high forward P/E of 9.96 despite a trailing P/E of 28.38, suggesting optimism around earnings recovery. While revenue growth is robust (71.3% YoY), earnings growth is negative (-14.4% YoY), and the dividend payout ratio is dangerously high at 169.44%, raising sustainability concerns. Analysts are strongly bullish with a $55.01 target price, but weak recent earnings beats (1 of last 4) and bearish technicals (0/100) create conflicting signals.

TSCO exhibits a stable deterministic health profile with a Piotroski F-Score of 6/9, yet it is severely overvalued relative to its Graham Number ($15.07) and Intrinsic Value ($14.42). While the company maintains an exceptional ROE of 45.18%, this is offset by negative earnings growth (-2.20% YoY) and a dangerously low Quick Ratio of 0.09, indicating heavy reliance on inventory for liquidity. The combination of a 0/100 technical trend, aggressive insider selling ($11.96M), and a price trading at a massive premium to defensive fair value suggests significant downside risk.